Ajenat Pharma

Ajenat Pharma is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of cancer. The company's lead programs target metabolic vulnerabilities in tumor cells, specifically focusing on monocarboxylate transporters (MCTs) to disrupt cancer cell energy production and pH regulation. By inhibiting these transporters, Ajenat aims to provide new treatment options for patients with advanced solid tumors that are resistant to standard therapies. The company is headquartered in San Diego, California, and is led by an experienced management team with a proven track record in oncology drug discovery and development.